Eli Lilly's Alzheimer's drug donanemab to complete rolling FDA submission in 2022


2022-09-26: [Chinese Article Link] Compiling Tom Lee. According to the latest news, Renaissance plans to complete a rolling regulatory submission in the first quarter of 2022, thereby gaining a favourable position in the ensuing Alzheimer’s disease treatment competition. Lele promised that his candidate drug, Donado, for Alzheimer’s


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.




Trending in China

What China Reads


Eli Lilly's Alzheimer's drug donanemab to complete rolling FDA submission in 2022


2022-09-26: [Article Link] Compiling Tom Lee. According to the latest news, Renaissance plans to complete a rolling regulatory submission in the first quarter of 2022, thereby gaining a favourable position in the ensuing Alzheimer’s disease treatment competition. Lele promised that his candidate drug, Donado, for Alzheimer’s

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.